Abstracts are available on the ASGCT website. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced that five abstracts were accepted for the 23 rd Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place virtually from May 12-15, 2020. doi: 10.Intellia Therapeutics to Present New Preclinical Data from Its CRISPR/Cas9 Programs at the 23rd Annual Meeting of the American Society of Gene and Cell TherapyĬAMBRIDGE, Mass., Ap(GLOBE NEWSWIRE) - Intellia Therapeutics, Inc. Aptamers for Proteins Associated With Rheumatic Diseases: Progress, Challenges, and Prospects of Diagnostic and Therapeutic Applications. Shatunova EA, Korolev MA, Omelchenko VO, Kurochkina YD, Davydova AS, Venyaminova AG, et al. Aptamers in the Therapeutics and Diagnostics Pipelines. Glyn-Jones S, Palmer AJ, Agricola R, Price AJ, Vincent TL, Weinans H, et al. Current Evidence on Risk Factors for Knee Osteoarthritis in Older Adults: A Systematic Review and Meta-Analysis. Silverwood V, Blagojevic-Bucknall M, Jinks C, Jordan JL, Protheroe J, Jordan KP. History of Knee Injuries and Knee Osteoarthritis: A Meta-Analysis of Observational Studies. Muthuri SG, McWilliams DF, Doherty M, Zhang W. The use of CD200R1 agonists to blunt the inflammatory response in the knee are insufficient to prevent disease progression in the mouse DMM model of OA without anatomical restoration of the normal joint biomechanics.ĬD200R1 DMM aptamer mouse model osteoarthritis.Ĭopyright © 2022 Vachhani, Prodeus, Nakamura, Rockel, Hopfgartner, Kapoor, Gariépy, Whyne and Nam. We did not find any attenuation of cartilage degeneration or synovitis in DMM mice with CD200Fc or CCS13 at 12 weeks post-surgery, nor stereological differences in the properties of subchondral bone. Histopathological assessment was used as the primary outcome measure to assess cartilage and synovial changes, while ♜T imaging was used to compare the changes to the subchondral bone between untreated and treated arthritic groups.

Oligonucleotides were injected intra-articularly beginning one week after surgery, with a total of six injections administered prior to sacrifice at 12 weeks post-surgery. CCS13 was evaluated as a therapeutic treatment along with CD200Fc and a phosphate-buffered saline vehicle control. Ten week old male C57BL/6 mice were randomized and surgical destabilization of the medial meniscus (DMM) to induce knee arthritis or sham surgery as a control were performed. This study aimed to determine whether CD200R1 agonists, namely the protein therapeutic CD200Fc or the synthetic DNA aptamer CCS13, both known to act as anti-inflammatory agents, are able to delay the pathogenesis of injury-associated knee osteoarthritis in a murine model. Therapeutic targeting of inflammatory activity in the knee immediately post injury may alter the course of osteoarthritis development. Post-traumatic knee osteoarthritis is characterized by cartilage degeneration, subchondral bone remodeling, osteophyte formation, and synovial changes.

Aaron prodeus